Cargando…
Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients
Unrelated cord blood transplantation (UCBT) is an effective treatment for hematopoietic disorders. However, this attractive approach is frequently accompanied by pre-engraftment syndrome (PES), severe cases of PES are associated with enhanced mortality and morbidity, but the pathogenesis of PES rema...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260612/ https://www.ncbi.nlm.nih.gov/pubmed/34230468 http://dx.doi.org/10.1038/s41467-021-24412-1 |
_version_ | 1783718843524317184 |
---|---|
author | Jin, Linlin Sun, Zimin Liu, Huilan Zhu, Xiaoyu Zhou, Yonggang Fu, Binqing Zheng, Xiaohu Song, Kaidi Tang, Baolin Wu, Yun Zhu, Jiang Sun, Rui Tian, Zhigang Wei, Haiming |
author_facet | Jin, Linlin Sun, Zimin Liu, Huilan Zhu, Xiaoyu Zhou, Yonggang Fu, Binqing Zheng, Xiaohu Song, Kaidi Tang, Baolin Wu, Yun Zhu, Jiang Sun, Rui Tian, Zhigang Wei, Haiming |
author_sort | Jin, Linlin |
collection | PubMed |
description | Unrelated cord blood transplantation (UCBT) is an effective treatment for hematopoietic disorders. However, this attractive approach is frequently accompanied by pre-engraftment syndrome (PES), severe cases of PES are associated with enhanced mortality and morbidity, but the pathogenesis of PES remains unclear. Here we show that GM-CSF produced by cord blood-derived inflammatory monocytes drives PES pathology, and that monocytes are the main source of IL-6 during PES. Further, we report the outcome of a single arm, single-center clinical study of tocilizumab in the treatment of steroid-refractory severe PES patients (www.chictr.org.cn ChiCTR1800015472). The study met the primary outcome measure since none of the patients was nonrelapse death during the 100 days follow-up. The study also met key secondary outcomes measures of neutrophil engraftment and hematopoiesis. These findings offer a therapeutic strategy with which to tackle PES and improve nonrelapse mortality. |
format | Online Article Text |
id | pubmed-8260612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82606122021-07-23 Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients Jin, Linlin Sun, Zimin Liu, Huilan Zhu, Xiaoyu Zhou, Yonggang Fu, Binqing Zheng, Xiaohu Song, Kaidi Tang, Baolin Wu, Yun Zhu, Jiang Sun, Rui Tian, Zhigang Wei, Haiming Nat Commun Article Unrelated cord blood transplantation (UCBT) is an effective treatment for hematopoietic disorders. However, this attractive approach is frequently accompanied by pre-engraftment syndrome (PES), severe cases of PES are associated with enhanced mortality and morbidity, but the pathogenesis of PES remains unclear. Here we show that GM-CSF produced by cord blood-derived inflammatory monocytes drives PES pathology, and that monocytes are the main source of IL-6 during PES. Further, we report the outcome of a single arm, single-center clinical study of tocilizumab in the treatment of steroid-refractory severe PES patients (www.chictr.org.cn ChiCTR1800015472). The study met the primary outcome measure since none of the patients was nonrelapse death during the 100 days follow-up. The study also met key secondary outcomes measures of neutrophil engraftment and hematopoiesis. These findings offer a therapeutic strategy with which to tackle PES and improve nonrelapse mortality. Nature Publishing Group UK 2021-07-06 /pmc/articles/PMC8260612/ /pubmed/34230468 http://dx.doi.org/10.1038/s41467-021-24412-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jin, Linlin Sun, Zimin Liu, Huilan Zhu, Xiaoyu Zhou, Yonggang Fu, Binqing Zheng, Xiaohu Song, Kaidi Tang, Baolin Wu, Yun Zhu, Jiang Sun, Rui Tian, Zhigang Wei, Haiming Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients |
title | Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients |
title_full | Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients |
title_fullStr | Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients |
title_full_unstemmed | Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients |
title_short | Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients |
title_sort | inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260612/ https://www.ncbi.nlm.nih.gov/pubmed/34230468 http://dx.doi.org/10.1038/s41467-021-24412-1 |
work_keys_str_mv | AT jinlinlin inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT sunzimin inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT liuhuilan inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT zhuxiaoyu inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT zhouyonggang inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT fubinqing inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT zhengxiaohu inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT songkaidi inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT tangbaolin inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT wuyun inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT zhujiang inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT sunrui inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT tianzhigang inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients AT weihaiming inflammatorymonocytespromotepreengraftmentsyndromeandtocilizumabcantherapeuticallylimitpathologyinpatients |